This is a summary of three articles describing preventive treatment of migraine in participants with a diagnosis of both chronic migraine and medication-overuse headache in a study called PROMISE-2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2). People living with chronic migraine and medication-overuse headache have one of the most disabling, costly, and difficult-to-treat headache disordersThis Plain Language Summary of Publication from Pain Management summarises a study called PROMISE-2 looking at three articles describing preventive treatment for migraines in people who have both chronic migraine and medication-overuse headache. A medication called eptinezumab was found to be beneficial for people who use over the counter/prescription medication to treat frequent headaches and migraine attacks.

Read the full article here.

The original articles on which this summary is based were  published in Headache, they are listed below.

  • ‘Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE’. You can read it here.
  • ‘Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication overuse headache’. You can read it here.
  • ‘Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial’. You can read it here.